Table 3:
Number of patients with HIV risk scores above specific percentile thresholds in the general populationa and among those with incident HIV infection or PrEP use in the three study cohorts.
| Atrius Health, 2007-2015 (n=1,154,964) | Atrius Health, 2016 (n=536,528) | Fenway Health, 2011-2016 (n=30,938) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Percentile of HIV risk scoreb |
Risk score (out of 100,000) |
General population (n=1,154,724) n (%) |
Incident HIV infection (n=150) n (%) |
PrEP use (n=90) n (%) |
General population (n=536,384) n (%) |
Incident HIV infection (n=16) n (%) |
PrEP use (n=128) n (%) |
General population (n=28,702) n (%) |
Incident HIV infection (n=423) n (%) |
PrEP use (n=1,813) n (%) |
| 10% | 0 | 399,385 (34·6) | 150 (100·0) | 90 (100) | 245,459 (45·8) | 16 (100) | 128 (100·0) |
28,702 (100·0) | 423 (100·0) | 1,813 (100·0) |
| 20% | 0 | 399,385 (34·6) | 150 (100·0) | 90 (100) | 245,459 (45·8) | 16 (100) | 128 (100·0) |
28,702 (100·0) | 423 (100·0) | 1,813 (100·0) |
| 30% | 0 | 399,385 (34·6) | 150 (100·0) | 90 (100) | 245,459 (45·8) | 16 (100) | 128 (100·0) |
28,702 (100·0) | 423 (100·0) | 1,813 (100·0) |
| 40% | 0 | 399,385 (34·6) | 150 (100·0) | 90 (100) | 245,459 (45·8) | 16 (100) | 128 (100·0) |
28,702 (100·0) | 423 (100·0) | 1,813 (100·0) |
| 50% | 0 | 399,385 (34·6) | 150 (100·0) | 90 (100) | 245,459 (45·8) | 16 (100) | 128 (100·0) |
28,702 (100·0) | 423 (100·0) | 1,813 (100·0) |
| 60% | 0 | 399,385 (34·6) | 150 (100·0) | 90 (100) | 245,459 (45·8) | 16 (100) | 128 (100·0) |
28,702 (100·0) | 423 (100·0) | 1,813 (100·0) |
| 70% | 1 | 342,911 (29·7) | 144 (96·0) | 90 (100) | 173,639 (32·4) | 16 (100) | 128 (100·0) |
28,125 (98·0) | 423 (100·0) | 1,810 (99–8) |
| 80% | 2 | 225,988 (19·6) | 142 (94·7) | 90 (100) | 129,767 (24·2) | 16 (100) | 128 (100·0) |
21,015 (73·2) | 415 (98·1) | 1,792 (98·8) |
| 90% | 8 | 115,269 (10·0) | 116 (77·3) | 88 (98) | 48,533 (9·0) | 15 (94) | 115 (89·8) |
16,023 (55·8) | 386 (91·3) | 1,721 (94·9) |
| 91% | 9 | 103,623 (9·0) | 107 (71·3) | 88 (98) | 47,708 (8·9) | 15 (94) | 114 (89·0) |
15,690 (54·7) | 385 (91·0) | 1,706 (94·1) |
| 92% | 10 | 92,278 (8·0) | 105 (70·0) | 88 (98) | 40,961 (7·6) | 13 (81) | 108 (84·4) |
14,861 (51·8) | 370 (87·5) | 1,672 (92·2) |
| 93% | 11 | 76,263 (6·6) | 105 (70·0) | 88 (98) | 34,041 (6·3) | 13(81) | 106 (82·8) |
14,016 (48·8) | 362 (85·6) | 1,623 (89·5) |
| 94% | 12 | 67,508 (5·8) | 103 (68·7) | 88 (98) | 28,572 (5·3) | 12 (75) | 102 (79·7) |
13,045 (45·4) | 351 (83·0) | 1,569 (86·5) |
| 95% | 13 | 57,470 (5·0) | 101 (67·3) | 88 (98) | 24,413 (4·6) | 10 (63) | 99 (77·3) | 11,732 (40·9) | 340 (80·4) | 1,533 (84·6) |
| 96% | 15 | 43,312 (3·8) | 97 (64·7) | 85 (94) | 18,854 (3·5) | 8 (50) | 90 (70·3) | 6,961 (24·3) | 225 (53·2) | 1,125 (62·1) |
| 97% | 18 | 34,247 (3·0) | 85 (56·7) | 83 (92) | 15,101 (2·8) | 8 (50) | 82 (64·0) | 5,997 (20·9) | 207 (48·9) | 1,039 (57·3) |
| 98% | 25 | 23,018 (2·0) | 76 (50·7) | 71 (79) | 9,515 (1·8) | 6 (38) | 62 (48·4) | 4,385 (15·3) | 196 (46·3) | 851 (46·9) |
| 99% | 32 | 11,352 (1·0) | 62 (41·3) | 56 (62) | 5,192 (1·0) | 4 (25) | 53 (41·4) | 2,284 (8·0) | 131 (31·0) | 672 (37·1) |
PrEP, preexposure prophylaxis.
a
Excludes patients already diagnosed with HIV infection for all study cohorts, for whom HIV risk scores would not be meaningful.
b
HIV risk scores were calculated by applying the LASSO model to the development sample.